Edwards Lifesciences Reports Fourth Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to Edwards Lifesciences Reports Fourth Quarter Results
February 3, 2016 10:06 AM EST
Canaccord Genuity reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $92.00 (from $90.00), following the company's 4Q. Checks imply growing acceptance of TAVI as a durable therapy for severe, symptomatic aortic valve disease, with predictable outcomes and consistent results rapidly... More
February 3, 2016 7:42 AM EST
Piper Jaffray analyst Brooks West reiterated an Overweight rating and boosted his price target on Edwards Lifesciences (NYSE: EW) to $97.00 (from $90.00) following a strong finish to 2015 and higher 2016 guidance.
West commented, "Edwards reported Q4 revenues of $671.1M, beating our estimate of $647.7M and consensus $648.8M. Upside... More
February 2, 2016 4:17 PM EST
Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.63, $0.01 better than the analyst estimate of $0.62. Revenue for the quarter came in at $671.1 million versus the consensus estimate of $648.74 million.
GUIDANCE:
Edwards Lifesciences sees FY2016 EPS of $2.57-$2.67, versus the consensus... More
